2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
7
Ovarian Neoplasms
6
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma, Ewing
4
Leukemia
4
Uterine Neoplasms
3
Uterine Cervical Neoplasms
3
Neoplasms
3
Multiple Myeloma
3
Kidney Neoplasms
3
Gliosarcoma
3
Glioblastoma
3
Central Nervous System Neoplasms
3
Carcinoma, Renal Cell
3
Astrocytoma
3
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Lymphoma, Follicular
2
Lymphoma
2
Fallopian Tube Neoplasms
2
Congenital Abnormalities
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms
2
Brain Neoplasms
2
Thymoma
1
Small Cell Lung Carcinoma
1
Interventions
Cyclophosphamide
9
Pemetrexed
6
pembrolizumab
5
fludarabine
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
ponatinib
4
atezolizumab
4
Rituximab
4
Dexamethasone
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
Sunitinib
3
Melphalan
3
Lutetium
3
Doxorubicin
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
pomalidomide
2
osimertinib
2
napabucasin
2
isatuximab
2
fludarabine phosphate
2
ficlatuzumab
2
entrectinib
2
entinostat
2
durvalumab
2
cobimetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts